Key result
Overexpression of rbFOX1 competes with MBNL1 for binding to expanded CCUG RNA repeats, correcting alternative splicing and rescuing muscle atrophy and locomotor defects in a Drosophila model of DM2.
Why the study?
Does rbFOX1 overexpression rescue molecular and phenotypic defects in preclinical models of myotonic dystrophy type 2?
Does rbFOX1 overexpression rescue molecular and phenotypic defects in preclinical models of myotonic dystrophy type 2?
rbFOX1 competes with MBNL1 for binding to expanded CCUG RNA repeats, which may explain the milder clinical course of myotonic dystrophy type 2 compared to type 1 and highlights a potential therapeutic mechanism.
Supports rbFOX1 modulation in DM2; leaves open translation from Drosophila models to patients.
Myotonic dystrophy type 1 and type 2 (DM1, DM2) are caused by expansions of CTG and CCTG repeats, respectively. RNAs containing expanded CUG or CCUG repeats interfere with the metabolism of other RNAs through titration of the Muscleblind-like (MBNL) RNA binding proteins. DM2 follows a more favorable clinical course than DM1, suggesting that specific modifiers may modulate DM severity. Here, we report that the rbFOX1 RNA binding protein binds to expanded CCUG RNA repeats, but not to expanded CUG RNA repeats. Interestingly, rbFOX1 competes with MBNL1 for binding to CCUG expanded repeats and overexpression of rbFOX1 partly releases MBNL1 from sequestration within CCUG RNA foci in DM2 muscle cells. Furthermore, expression of rbFOX1 corrects alternative splicing alterations and rescues muscle atrophy, climbing and flying defects caused by expression of expanded CCUG repeats in a Drosophila model of DM2.
No takes yet. Share an insight, caveat, or question.
Sellier et al. (2018) studied Myotonic dystrophy type 1 and type 2. rbFOX1 overexpression vs. Control (no overexpression or CUG repeats) was evaluated on Rescue of muscle atrophy and locomotor defects in Drosophila model of DM2. Overexpression of rbFOX1 competes with MBNL1 for binding to expanded CCUG RNA repeats, correcting alternative splicing and rescuing muscle atrophy and locomotor defects in a Drosophila model of DM2.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: